|
|
||||||||
Review |
Address correspondence to Pai C. Kao, Ph.D., Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
C-reactive protein (CRP), a nonspecific inflammatory marker, is widely used to monitor treatment of cardiovascular diseases (high serum CRP levels indicate poor outcome of heart disease). A healthy lifestyle decreases serum CRP levels, while obesity, physical inactivity, and smoking increase them. CRP, a stable pentameric protein, has a half-life of 19 hr, is not subject to diurnal variation, and can serve as a marker of wellness and a candidate for future direct access testing for people monitoring their health after adopting a healthier lifestyle. The CRP level may be influenced more by lifestyle than by genetics. Monozygotic twins may not have the same CRP level; within each twin pair, the one with higher adiposity generally has a higher CRP level than the one with low adiposity. Chronic diseases generally have a lower prevalence among Asians than among Westerners. Asians also have lower CRP levels than Westerners. In large population studies, the median CRP level of Asians is only one-tenth that of Westerners. Is there a factor in the lifestyle or diet of Asians that accounts for lower CRP levels? For example, a statin inhibitor of cholesterol synthesis occurs in red yeast rice, an important component of the Asian diet. In summary, CRP is a marker for monitoring cardiovascular therapy and assessing the wellness of the general population. Through improving health and preventing disease, CRP testing may help lower a nations health costs.
Keywords: body mass index, C-reactive protein, wellness assessment, health screening
This article has been cited by other articles:
![]() |
G. S. Metsios, A. Stavropoulos-Kalinoglou, V. F. Panoulas, Y. Koutedakis, A. M. Nevill, K. M. J. Douglas, M. Kita, and G. D. Kitas New resting energy expenditure prediction equations for patients with rheumatoid arthritis Rheumatology, April 1, 2008; 47(4): 500 - 506. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-J. Wu, H.-Y. Ou, C.-W. Chou, S.-H. Hsiao, C.-Y. Lin, and P. C. Kao Decrease in Inflammatory Cardiovascular Risk Markers in Hyperlipidemic Diabetic Patients Treated with Fenofibrate Ann. Clin. Lab. Sci., January 1, 2007; 37(2): 158 - 166. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Walley, A. I.F. Blakemore, and P. Froguel Genetics of obesity and the prediction of risk for health Hum. Mol. Genet., October 15, 2006; 15(suppl_2): R124 - R130. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |